Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension

Physiological Research

Volumn 55, Issue 6, 2006, Pages 597-602

  Petrak O ^a,b   Widimsky Jr J ^a   Zelinka, T ^a   Kvasnicka J ^a   Strauch B ^a   Holaj, R ^a   Stulc T ^a   Kvasnicka T ^a   Bilkova J ^a   Skrha J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adhesive molecules; Endothelial dysfunction; Essential hypertension; Pheochromocytoma; Primary hyperaldosteronism

Indexed keywords

ALDOSTERONE; BIOCHEMICAL MARKER; CATECHOLAMINE; DOXAZOSIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PROTEIN ANALYSIS;

ADRENAL GLAND NEOPLASMS; BIOLOGICAL MARKERS; BLOOD PRESSURE; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 33845909816     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BALLANTYNE CM, ENTMAN ML: Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 106: 766-767, 2002.
2. BLUHER, UNGER R, RASSOUL F, RICHTER V, PASCHKE R: Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 45: 210-216, 2002.
3. CAO JJ, THACH C, MANOLIO TA, PSATY BM, KULLER LH, CHAVES PHM, POLAK JF, SUTTON-TYRRELL K, HERRINGTON DM, PRICE TR, CUSHMAN MC: Reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. Circulation 108: 166-170, 2003.
4. CONTRERAS F, RIVERA M, VÁSQUEZ J, DE LA PARTE MA, VELASCO M: Endothelial dysfunction in arterial hypertension. J Hypertens 14 (Suppl 1): S20-S25, 2000.
5. DE CATERINA R, GHIADONI L, TADDEI S, VIRDIS A, ALMERIGOGNA F, BASTA G, LAZZERINI G, BERNINI W, SALVETTI A: Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 1: 259-266, 2001.
6. FIALOVÁ L: New findings in pathogenesis of arteriosclerosis. Ceska Fyziol 2: 92-101, 1995.
7. GUERCI B, KEARNEY-SCHWARTZ A, BOHME P, ZANNAD F, DROUIN P: Endothelial dysfunction and type 2 diabetes. Diabetes Metab 27: 425-434, 2001.
8. HALLER H, COSENTINO F, LÜSCHER TF: Endothelial dysfunction, hypertension and atherosclerosis. Drugs R D 3: 311-323, 2002.
9. HILLIS GS: Soluble integrin adhesion receptors and atherosclerosis: much heat and a little light? J Hypertens 17: 449-453, 2003.
10. HLUBOCKÁ Z, UMNEROVÁ V, HELLER S, PELEŠKA J, JINDRA A, JÁCHYMOVÁ M, KVASNIÈKA J, HORKÝ K, ASCHERMANN M: Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor - markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hypertens 16: 557-562, 2002.
11. HUO Y, LEY K: Adhesion molecules and atherogenesis. Acta Physiol Scand 173: 35-43, 2001.
12. LEE AJ: Haemorheological, platelet and endothelial factors in essential hypertension. J Hum Hypertens 16: 529-531, 2002.
13. LIBBY P, RIDKER OM, MASERI A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
14. LIPP GY, BLANN A: Von Willebrand factor a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34: 255-265, 1997.
15. MACIAS C, VILLAESCUSA R, DEL VALLE L, BOFFIL V, CORDERO G, HERNANDEZ A, HERNANDEZ P, BALLESTER JM: Endothelial adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with acute coronary syndrome. Rev Esp Cardiol 56: 137-144, 2003.
16. MAHMUD A, FEELY J: Arterial stiffness and the renin-angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 5: 102-108, 2004.
17. MAKRIS TK, TSOUKALA C, KRESPI P, HATZIZACHARIAS A, GIALERAKI A, PAPARGYRIOU J, VOTTEAS V, MANDALAKI T: Haemostasis balance disorders in patients with essential hypertension. Thromb Res 88: 99-107, 1997.
18. NAVAB M, ANANTHARAMAIAH GM, FOGELMAN AM: The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 15: 158-61, 2005.
19. RIDKER PM, CUSHMAN M, STAMPFER MJ:. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979, 1997.
20. RIZZONI D, PORTERI E, CASTELLANO M, BETTONI G, MUIESAN ML, TIBERIO G, GIULINI SM, ROSSI G, BERNINI G, AGABITI-ROSEI E: Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 31: 335-341, 1998.
21. SUNG KC, SUH JY, KIM BS, KANG JH, KIN H, LEE MH, PARK JR, KIM SW: High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 16: 429-433, 2003.
22. TOUZE JE, MONNIER A, MARDELLE T, SEKA R, METRAS D, BERTRAND E: Early coronary atherosclerosis in a malignant pheochromocytoma. Sem Hop 60: 1010-1013, 1984.
23. VAN DER MEER IM, M DE MAAT MP, BOTS ML, BRETELER MMB, MEIJER J, KILIAAN AJ, HOFMAN A, WITTEMAN JCM: Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis. The Rotterdam Study. Arterioscler Thromb Vasc Biol 22: 838-842, 2002.
24. ZELINKA T, ŠTRAUCH B, PECEN L, WIDIMSKÝ J Jr: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 18: 107-111, 2004.
25. ZELINKA T, ŠTRAUCH B, PETRÁK O, HOLAJ R, VRÁNKOVÁ A, WEISSEROVÁ H, PACÁK K, WIDIMSKÝ J Jr: Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens 23: 2033-2039, 2005.